$2.96B in Life Science Funding

CipherBio Weekly Digest: Week of Feb 10 – Feb 16, 2022

This week our life science funding digest reports $2.77B in deals and $391.90M in Series A. We also added 105 companies and 42 investors to our platform.

$2.96B
Deals

$789.04M
Series A

$647.7M
Later Rounds

$900M
M&A/IPOs

105
New Companies on CipherBio

42
New Investors on CipherBio

Sign Up For Your Free Account ➜

Top Deals This Week

Upstream Bio, Cambridge-based biotech, raises $200M in Series A round led by Orbimed. A FoodTech company Next Gen Foods raises $100M in Series A from Temasek Holdings, K3 Ventures, GGV Capital and others. Leyden Labs raises $140M in Series B led by Casdin Capital and GV. Also in Series B Third Harmonic Bio raises $105M led by General Atlantic and BVF Partners. Kallyope gets $150M in Series D led by Mubadala Investment Company and The Column Group. Collegium Pharmaceutical acquires BioDelivery Sciences in an all-cash deal worth up to $604M.

Company	Round	Amount
Upstream Bio	Series A	$200M
Next Gen Foods	Series A	$100M
Leyden Labs	Series B	$140M
Third Harmonic Bio	Series B	$105M
Kallyope	Series D	$150M
Collegium Pharmaceutical	Acquisition	$604M

Funds Raised This Week

ACME Capital, San Francisco VC, raises $300M in ACME Fund IV from undisclosed investors. Asia Healthcare Holdings(AHH) raises $170M in Wealth Fund GIC from undisclosed investors. Unovis Asset Management closes $166M Unovis Asset Management’s Fund II from Unigestion, Invest-NL, Griffith Foods and others.

This Week’s Lead Investors in Top Rounds

Lead investors this week are Orbimed, Temasek, Casdin Capital, GV, General Atlantic, BVF Partners, Mubadala Investment Company and The Column Group.

See Investors Insights ➜

This Week in Clinical Phases

In phase 1 Maze Therapeutics announces trial of MZE001 for Pompe Disease. Belgium-based Oxurion announces phase 2 clinical trial of THR-149. Revive Therapeutics is in phase 3 trial of Bucillamine. Motus GI got the FDA Clearance for its Pure-Vu® EVS System.

Company	Product and Clinical Phase	Indications
Maze Therapeutics	MZE001, Phase 1	Pompe Disease
Oxurion	THR-149, Phase 2	Diabetic Macular Edema
Revive Therapeutics	Bucillamine, Phase 3	Liver Diseases, Autoimmune Hepatitis, COVID-19
Motus GI	Pure-Vu® EVS System, FDA Cleared	Gastrointestinal Diseases

Starfield, food & science technology, raised $100M in Series B round led by Primavera Capital Group, Lightspeed China Partners and Joy Capital. FlipDish raised $100M in Series C led by Tencent. In AgTech MycoWorks raised $125M in Series C to build a new alt-leather factory. WayCool raised $117M in Series D led by LightRock, LightBox, FMO and others.

105 Life Science Companies Added

This week we added 154 funding events, 105 life science companies and 42 investors.

eAgronom	Scopio Labs	VisuWell
Ada Health	Splendid Spoon	LinKinVax
Respira Labs	PhaseBio Pharmaceuticals	Bodymatter
Elo Health	Birmingham Biotech	Protix
Endless West	Celeris Therapeutics	Mindstate Design Labs